Found 29 Alzheimer's Disease trials
A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Test Trial - v7.0What is the purpose of this study?This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with …
The research study is being conducted to learn about the work of breathing support that an external breathing support device can provide compared to a person’s baseline ability. The research study is sponsored by RightAir Inc, the makers of the device being investigated, the AIR-AD cuirass ventilator. This study is …
The Study is two research trials aimed at preventing Alzheimer’s disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. AHEAD-3 studies people with intermediate amyloid, while AHEAD-45 studies people with elevated amyloid. Research studies are designed to gain scientific knowledge that may help people in the …
The aim of the Alzheimers Disease Neuroimaging Initiative (ADNI) has been to validate biomarkers for Alzheimers disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic …
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
This open-label, single arm clinical study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer's disease who were actively participating in Aducanumab clinical studies 103, 205, 301, or 302 (aducanumab feeder studies) as of March 21st 2019. Participants who participated in 221AD302 will …
Evaluate the safety, tolerability, and immunogenicity of 3 dose levels of PR006A administered via sub-occipital injection into the cisterna magna and Quantify PGRN levels in blood and CSF. Please refer to section 2 of the attached protocol. Please refer to section 2 of the attached protocol.
The research study is being conducted to test the safety and tolerability (i.e., possible side effects) of an investigational drug called AL001 and to find out what effects AL001 has on the body. This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study …
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
